Related Experiment Video
Updated: Oct 3, 2025
07:40
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.3K
A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy
Michael Osekowski1, Adam Trytell1, Andre La Gerche1,2,3
1St Vincent's Hospital Melbourne, Fitzroy, VIC, 3065, Australia.
Summary
Methamphetamine-associated cardiomyopathy (MAC) is a growing global health concern. Effective management requires methamphetamine abstinence, optimal heart failure therapy, and multidisciplinary support for better patient outcomes.
Area of Science:
- Cardiology
- Toxicology
- Public Health
Background:
- Methamphetamine use is increasing globally, leading to a rise in methamphetamine-associated cardiomyopathy (MAC).
- MAC presents with high rates of sudden cardiac arrest, delayed diagnosis, and poor prognosis.
- Patients with MAC are often younger and have multisystem disease compared to other cardiomyopathy types.
Purpose of the Study:
- To review the medical management of methamphetamine-associated cardiomyopathy.
- To identify challenges in treating MAC patients, particularly those related to methamphetamine use.
- To emphasize optimal treatment strategies for improved patient outcomes.
Main Methods:
- This is a review article discussing the medical management of MAC.
- It synthesizes current knowledge on MAC diagnosis, treatment, and challenges.
- Focuses on the specific needs of methamphetamine users.
Main Results:
- MAC management requires addressing unique challenges in methamphetamine users, including behavioral and psychosocial factors.
- Individualized treatment plans are crucial, prioritizing methamphetamine abstinence.
- Optimal heart failure therapy and multidisciplinary support are essential for recovery.
Conclusions:
- Methamphetamine-associated cardiomyopathy is potentially reversible.
- Abstinence from methamphetamine is the cornerstone of effective MAC treatment.
- Guideline-directed heart failure therapy, coupled with robust patient support, is vital for optimal outcomes.
More Related Videos
09:16A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
15.4K
05:04In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
3.5K
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
56
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
56
01:14Myocarditis III: Medical Management
27
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
27
01:30Cardiomyopathy II: Dilated Cardiomyopathy
50
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
50
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
78
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
78
01:22Myocarditis IV: Nursing Management
49
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
49
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
77
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
77